Abstract
Summary
The global Tumor NGS Detection market size is projected to grow from US$ 1795.1 million in 2022 to US$ 5194.1 million in 2029; it is expected to grow at a CAGR of 16.4% from 2023 to 2029.
United States market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor NGS Detection players cover Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq and AmoyDx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
The main purpose of NGS is to discover clinically treatable genetic variants and guide patient treatment.
LPI (LP Information)' newest research report, the “Tumor NGS Detection Industry Forecast” looks at past sales and reviews total world Tumor NGS Detection sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor NGS Detection sales for 2023 through 2029. With Tumor NGS Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor NGS Detection industry.
This Insight Report provides a comprehensive analysis of the global Tumor NGS Detection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor NGS Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor NGS Detection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor NGS Detection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor NGS Detection.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor NGS Detection market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Medical Equipment
Consumables
Segmentation by application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent
Thermo Fisher Scientific
BGI Group
Roche Foundation Medicine
Sinopharm Group
Fosunpharma
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
Perkin Elmer
Qiagen NV
Partek
Illumina Inc.
Pacific Biosciences of California Inc.
Life Technologies Corporation
GTH.O
Paradigm Diagnostics
Oxford Nanopore Technologies Ltd.
Eurofins Scientific S.E.
United States market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor NGS Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor NGS Detection players cover Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq and AmoyDx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
The main purpose of NGS is to discover clinically treatable genetic variants and guide patient treatment.
LPI (LP Information)' newest research report, the “Tumor NGS Detection Industry Forecast” looks at past sales and reviews total world Tumor NGS Detection sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor NGS Detection sales for 2023 through 2029. With Tumor NGS Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor NGS Detection industry.
This Insight Report provides a comprehensive analysis of the global Tumor NGS Detection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor NGS Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor NGS Detection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor NGS Detection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor NGS Detection.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor NGS Detection market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Medical Equipment
Consumables
Segmentation by application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent
Thermo Fisher Scientific
BGI Group
Roche Foundation Medicine
Sinopharm Group
Fosunpharma
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
Perkin Elmer
Qiagen NV
Partek
Illumina Inc.
Pacific Biosciences of California Inc.
Life Technologies Corporation
GTH.O
Paradigm Diagnostics
Oxford Nanopore Technologies Ltd.
Eurofins Scientific S.E.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor NGS Detection Market Size 2018-2029
2.1.2 Tumor NGS Detection Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Tumor NGS Detection Segment by Type
2.2.1 Medical Equipment
2.2.2 Consumables
2.3 Tumor NGS Detection Market Size by Type
2.3.1 Tumor NGS Detection Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Tumor NGS Detection Market Size Market Share by Type (2018-2023)
2.4 Tumor NGS Detection Segment by Application
2.4.1 Companion Diagnostics
2.4.2 Early Cancer Screening
2.4.3 Drug Discovery
2.4.4 Other
2.5 Tumor NGS Detection Market Size by Application
2.5.1 Tumor NGS Detection Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Tumor NGS Detection Market Size Market Share by Application (2018-2023)
3 Tumor NGS Detection Market Size by Player
3.1 Tumor NGS Detection Market Size Market Share by Players
3.1.1 Global Tumor NGS Detection Revenue by Players (2018-2023)
3.1.2 Global Tumor NGS Detection Revenue Market Share by Players (2018-2023)
3.2 Global Tumor NGS Detection Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Tumor NGS Detection by Regions
4.1 Tumor NGS Detection Market Size by Regions (2018-2023)
4.2 Americas Tumor NGS Detection Market Size Growth (2018-2023)
4.3 APAC Tumor NGS Detection Market Size Growth (2018-2023)
4.4 Europe Tumor NGS Detection Market Size Growth (2018-2023)
4.5 Middle East & Africa Tumor NGS Detection Market Size Growth (2018-2023)
5 Americas
5.1 Americas Tumor NGS Detection Market Size by Country (2018-2023)
5.2 Americas Tumor NGS Detection Market Size by Type (2018-2023)
5.3 Americas Tumor NGS Detection Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor NGS Detection Market Size by Region (2018-2023)
6.2 APAC Tumor NGS Detection Market Size by Type (2018-2023)
6.3 APAC Tumor NGS Detection Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Tumor NGS Detection by Country (2018-2023)
7.2 Europe Tumor NGS Detection Market Size by Type (2018-2023)
7.3 Europe Tumor NGS Detection Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor NGS Detection by Region (2018-2023)
8.2 Middle East & Africa Tumor NGS Detection Market Size by Type (2018-2023)
8.3 Middle East & Africa Tumor NGS Detection Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Tumor NGS Detection Market Forecast
10.1 Global Tumor NGS Detection Forecast by Regions (2024-2029)
10.1.1 Global Tumor NGS Detection Forecast by Regions (2024-2029)
10.1.2 Americas Tumor NGS Detection Forecast
10.1.3 APAC Tumor NGS Detection Forecast
10.1.4 Europe Tumor NGS Detection Forecast
10.1.5 Middle East & Africa Tumor NGS Detection Forecast
10.2 Americas Tumor NGS Detection Forecast by Country (2024-2029)
10.2.1 United States Tumor NGS Detection Market Forecast
10.2.2 Canada Tumor NGS Detection Market Forecast
10.2.3 Mexico Tumor NGS Detection Market Forecast
10.2.4 Brazil Tumor NGS Detection Market Forecast
10.3 APAC Tumor NGS Detection Forecast by Region (2024-2029)
10.3.1 China Tumor NGS Detection Market Forecast
10.3.2 Japan Tumor NGS Detection Market Forecast
10.3.3 Korea Tumor NGS Detection Market Forecast
10.3.4 Southeast Asia Tumor NGS Detection Market Forecast
10.3.5 India Tumor NGS Detection Market Forecast
10.3.6 Australia Tumor NGS Detection Market Forecast
10.4 Europe Tumor NGS Detection Forecast by Country (2024-2029)
10.4.1 Germany Tumor NGS Detection Market Forecast
10.4.2 France Tumor NGS Detection Market Forecast
10.4.3 UK Tumor NGS Detection Market Forecast
10.4.4 Italy Tumor NGS Detection Market Forecast
10.4.5 Russia Tumor NGS Detection Market Forecast
10.5 Middle East & Africa Tumor NGS Detection Forecast by Region (2024-2029)
10.5.1 Egypt Tumor NGS Detection Market Forecast
10.5.2 South Africa Tumor NGS Detection Market Forecast
10.5.3 Israel Tumor NGS Detection Market Forecast
10.5.4 Turkey Tumor NGS Detection Market Forecast
10.5.5 GCC Countries Tumor NGS Detection Market Forecast
10.6 Global Tumor NGS Detection Forecast by Type (2024-2029)
10.7 Global Tumor NGS Detection Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Agilent
11.1.1 Agilent Company Information
11.1.2 Agilent Tumor NGS Detection Product Offered
11.1.3 Agilent Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Agilent Main Business Overview
11.1.5 Agilent Latest Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Information
11.2.2 Thermo Fisher Scientific Tumor NGS Detection Product Offered
11.2.3 Thermo Fisher Scientific Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Main Business Overview
11.2.5 Thermo Fisher Scientific Latest Developments
11.3 BGI Group
11.3.1 BGI Group Company Information
11.3.2 BGI Group Tumor NGS Detection Product Offered
11.3.3 BGI Group Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 BGI Group Main Business Overview
11.3.5 BGI Group Latest Developments
11.4 Roche Foundation Medicine
11.4.1 Roche Foundation Medicine Company Information
11.4.2 Roche Foundation Medicine Tumor NGS Detection Product Offered
11.4.3 Roche Foundation Medicine Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Roche Foundation Medicine Main Business Overview
11.4.5 Roche Foundation Medicine Latest Developments
11.5 Sinopharm Group
11.5.1 Sinopharm Group Company Information
11.5.2 Sinopharm Group Tumor NGS Detection Product Offered
11.5.3 Sinopharm Group Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sinopharm Group Main Business Overview
11.5.5 Sinopharm Group Latest Developments
11.6 Fosunpharma
11.6.1 Fosunpharma Company Information
11.6.2 Fosunpharma Tumor NGS Detection Product Offered
11.6.3 Fosunpharma Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Fosunpharma Main Business Overview
11.6.5 Fosunpharma Latest Developments
11.7 Novogene
11.7.1 Novogene Company Information
11.7.2 Novogene Tumor NGS Detection Product Offered
11.7.3 Novogene Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novogene Main Business Overview
11.7.5 Novogene Latest Developments
11.8 Geneseeq
11.8.1 Geneseeq Company Information
11.8.2 Geneseeq Tumor NGS Detection Product Offered
11.8.3 Geneseeq Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Geneseeq Main Business Overview
11.8.5 Geneseeq Latest Developments
11.9 AmoyDx
11.9.1 AmoyDx Company Information
11.9.2 AmoyDx Tumor NGS Detection Product Offered
11.9.3 AmoyDx Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 AmoyDx Main Business Overview
11.9.5 AmoyDx Latest Developments
11.10 Burning Rock Medicine
11.10.1 Burning Rock Medicine Company Information
11.10.2 Burning Rock Medicine Tumor NGS Detection Product Offered
11.10.3 Burning Rock Medicine Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Burning Rock Medicine Main Business Overview
11.10.5 Burning Rock Medicine Latest Developments
11.11 Perkin Elmer
11.11.1 Perkin Elmer Company Information
11.11.2 Perkin Elmer Tumor NGS Detection Product Offered
11.11.3 Perkin Elmer Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Perkin Elmer Main Business Overview
11.11.5 Perkin Elmer Latest Developments
11.12 Qiagen NV
11.12.1 Qiagen NV Company Information
11.12.2 Qiagen NV Tumor NGS Detection Product Offered
11.12.3 Qiagen NV Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Qiagen NV Main Business Overview
11.12.5 Qiagen NV Latest Developments
11.13 Partek
11.13.1 Partek Company Information
11.13.2 Partek Tumor NGS Detection Product Offered
11.13.3 Partek Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Partek Main Business Overview
11.13.5 Partek Latest Developments
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Information
11.14.2 Illumina Inc. Tumor NGS Detection Product Offered
11.14.3 Illumina Inc. Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Illumina Inc. Main Business Overview
11.14.5 Illumina Inc. Latest Developments
11.15 Pacific Biosciences of California Inc.
11.15.1 Pacific Biosciences of California Inc. Company Information
11.15.2 Pacific Biosciences of California Inc. Tumor NGS Detection Product Offered
11.15.3 Pacific Biosciences of California Inc. Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Pacific Biosciences of California Inc. Main Business Overview
11.15.5 Pacific Biosciences of California Inc. Latest Developments
11.16 Life Technologies Corporation
11.16.1 Life Technologies Corporation Company Information
11.16.2 Life Technologies Corporation Tumor NGS Detection Product Offered
11.16.3 Life Technologies Corporation Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Life Technologies Corporation Main Business Overview
11.16.5 Life Technologies Corporation Latest Developments
11.17 GTH.O
11.17.1 GTH.O Company Information
11.17.2 GTH.O Tumor NGS Detection Product Offered
11.17.3 GTH.O Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 GTH.O Main Business Overview
11.17.5 GTH.O Latest Developments
11.18 Paradigm Diagnostics
11.18.1 Paradigm Diagnostics Company Information
11.18.2 Paradigm Diagnostics Tumor NGS Detection Product Offered
11.18.3 Paradigm Diagnostics Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Paradigm Diagnostics Main Business Overview
11.18.5 Paradigm Diagnostics Latest Developments
11.19 Oxford Nanopore Technologies Ltd.
11.19.1 Oxford Nanopore Technologies Ltd. Company Information
11.19.2 Oxford Nanopore Technologies Ltd. Tumor NGS Detection Product Offered
11.19.3 Oxford Nanopore Technologies Ltd. Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Oxford Nanopore Technologies Ltd. Main Business Overview
11.19.5 Oxford Nanopore Technologies Ltd. Latest Developments
11.20 Eurofins Scientific S.E.
11.20.1 Eurofins Scientific S.E. Company Information
11.20.2 Eurofins Scientific S.E. Tumor NGS Detection Product Offered
11.20.3 Eurofins Scientific S.E. Tumor NGS Detection Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Eurofins Scientific S.E. Main Business Overview
11.20.5 Eurofins Scientific S.E. Latest Developments
12 Research Findings and Conclusion